AzTrials
AzTrials

Healthy AdultsPhase 1EHVA P01NCT04844775

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

A Phase 1 study testing Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above) and DNA-HIV-PT123 4mg and CN54gp140/MPLA-L in people with Healthy Adults, run by ANRS, Emerging Infectious Diseases at 4 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

EHVA P01 is an international, phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Adults
What is being tested?
Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above) and DNA-HIV-PT123 4mg and CN54gp140/MPLA-L
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
4 sitesin 3 countries
Study dates
5 Aug 2022to 9 Sep 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy adults aged 18- 55 years on the day of screening
  • BMI between 18-30 kg/m2 (inclusive)
  • Unlikely to acquire HIV during follow-up
  • Willing and able to provide written informed consent
  • If female and of childbearing potential* age and not sterilised, willing to use a highly effective method of contraception from screening until 12 weeks after last injection
  • If male and not sterilised, willing to avoid impregnating female partners from screening until 12 weeks after last injection**
Show all 11Show fewer
  • Willing to avoid all other vaccines from 28 days before the first injection through to 28 days after subsequent study injections
  • Willing and able to comply with visit schedule and provide blood samples
  • Being covered by medical insurance or in National Healthcare System
  • A woman will be considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  • It is recommended that participants have an up to date vaccination status for any required immunisations including authorised COVID-19 vaccines

Who cannot join

  • Pregnant or lactating
  • Has a significant clinical history, physical finding on clinical examination during screening, or presence of a disease that is active or requires treatment to control it, including cardiac, respiratory, endocrine, metabolic, autoimmune, liver, neurological, oncological, psychiatric, immunosuppresive/immunodeficient or other disorders which in the opinion of the investigator is not compatible with healthy status, may compromise the volunteer's safety, preclude vaccination or compromise interpretation of the immune response to vaccine. Individuals with mild/moderate, well-controlled comorbidities are allowed.
  • HIV 1 or 2 infection or indeterminate test at screening
  • History of anaphylaxis or angioedema
  • History of severe or multiple allergies to drugs or pharmaceutical agents
  • Known hypersensitivity to any component of the vaccine formulation used in this trial
Show all 15Show fewer
  • History of severe local or general reaction to vaccination defined as
  • local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours
  • general: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
  • Receipt of any experimental vaccine within 5 years from screening.
  • Receipt of blood products or immunoglobulins within 18 weeks of screening.
  • Receipt any of immunosuppressive agents within 18 weeks of screening by any route other than skin and intranasal.
  • Detection of antibodies to hepatitis B \& C
  • Participating in another clinical trial with an investigational drug or device, or treated with an investigational drug within 28 days of screening
  • Any of the values that are confirmed on repeat testing as defined in protocol

Trial locations and contacts

4 sites in 3 countries.

4 sites in 3 countries

France2 sites

  • Hôpital Henri Mondor

    Créteil, Paris, 94010

  • CIC Cochin

    Paris, Paris Cedex 14, 75679

Other trials in France

Switzerland1 site

  • CHUV

    Lausanne, Canton of Vaud, 1011

Other trials in Switzerland

United Kingdom1 site

  • Chelsea and Westminster Hospital

    London, SW10 9NH

Other trials in United Kingdom

About this study

Official title: EHVA P01/ANRS VRI08: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

EHVA P01 is an international, phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults.

Read the detailed description

The study is looking at the use of a new vaccine against the HIV virus. There are two parts to the study. One part is open-label to assess the safety of this vaccine, since this will be the first time that it has been used in humans. The second part is to see how well, and for how long, the vaccine activates the immune system. But this trial is not looking at whether or not the vaccine is effective in terms of protection against HIV. It is just assessing whether and how well the immune system responds.

Since this is the first time the vaccine has been used in humans, the safety will be assessed initially in healthy young adults. 10 participants aged 18-55 years will be given one of two different doses (0.2 and 1.0 mg) by injection into the arm muscle. There will be careful monitoring for any reactions to the vaccine.

As long as there are no safety concerns, the second part of the study can then be started. This will see how well the immune system has been activated using different dose levels of the vaccine. About 60 participants aged 18-55 years will be given one of three doses schedules (0.2mg, 1.0mg of the new vaccine and 4.0mg of a conventional vaccine). Chance will determine which dose each individual is given. Participants are only blind to the dose of vaccine administered but laboratory technicians assessing the safety parameters and immune responses will be blinded. The vaccine is given by injection into the muscle of the upper arm. Two injections, four weeks apart, are needed for the first part of the trial. There are three vaccinations in part two of the trial. There are likely to be mild side-effects near to the injection site. There may also be more general side-effects such as headache, temperature and chills. Participants will be asked to record any symptoms in an online diary. In order to see how well the immune system is responding, participants will need to give blood samples at several time points. The vaccines are not made from HIV and cannot cause HIV infection. However, the vaccines are likely to cause participants to produce antibodies against HIV that are detected by the rapid HIV antibody tests that are used in routine testing and a test that detects and measures antibodies in the blood used for confirmation. It is recommended that participants have an up to date vaccination status for any required immunisations including authorised COVID-19 vaccines. Vaccination with licensed (including authorised COVID-19) vaccines should be avoided from 28 days before and after each injection .

An independent steering committee will regularly review the information on safety and look at the immune responses to see which dose of the candidate vaccine could go forward to effectiveness testing in future trials. Before this study can start, the protocol describing the procedures and information to be provided to volunteers will be reviewed by the national drug authority and a multi-centre research ethics committee in the participating countries.

Conditions
Healthy Adults
Being tested
Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above), DNA-HIV-PT123 4mg and CN54gp140/MPLA-L

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-LBiological

    1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.
    2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.

  • DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)Biological

    1. Drep-HIV-PT1 1mg (see above)
    2. Drep-HIV-PT1 1mg (see above)

  • DNA-HIV-PT123 4mg and CN54gp140/MPLA-LBiological

    1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef
    2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.
Study groups in NCT04844775
Study groupRoleWhat they receive
Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-LExperimental0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®) 0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe.
Receives: Biological: Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L
Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-LExperimental0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®) 0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe.
Receives: Biological: DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)
DNA HIV PT123 4mg and CN54gp140/MPLA-LExperimental1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe. 0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe.
Receives: Biological: DNA-HIV-PT123 4mg and CN54gp140/MPLA-L

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1- Dose Escalation- Any adverse reaction that results in a clinical decision to stop immunisations

    Any adverse reaction that results in a clinical decision that no further immunisations can be given

    Measured: From week 0 up to Week 4

  2. Part 2- Randomised Comparison - Any adverse reaction that results in a clinical decision to stop immunisations

    Any adverse reaction that results in a clinical decision that no further immunisations can be given

    Measured: From week 0 up to Week 9

  3. PART 2 Randomised comparison- Total IgG Binding antibody response rate

    1. Env-specific total IgG binding antibody response rates assessed by binding antibody multiplex assay (BAMA)
    2. Magnitude of Env-specific total IgG binding antibody responses to HIV-1 Env proteins assessed by binding antibody multiplex assay (BAMA)

    Measured: At week 26

Secondary outcomes (3)

  1. Part 1- Dose Escalation - Occurrence of Adverse events

    1. Grade 3 or worse local or systemic solicited adverse events
    2. Grade 1 or 2 local or systemic solicited adverse events
    3. Non-solicited adverse events
    4. Serious adverse events

    Measured: From week 0 to Week 11

  2. Part 1- Dose Escalation - Binding antibodies to ZM96gp140

    Binding antibodies to ZM96gp140 measured by ELISA

    Measured: At week 6 and Week 26

  3. PART 2 Randomised comparison- Total IgG binding antibody response rates

    1. Env-specific total IgG binding antibody response rates assessed by binding antibody multiplex assay (BAMA)
    2. Magnitude of Env-specific total IgG binding antibody responses to HIV-1 Env proteins assessed by binding antibody multiplex assay (BAMA)
    3. Breadth of Env-specific total IgG binding antibody responses to HIV-1 Env proteins assessed by binding antibody multiplex assay (BAMA)
    4. Durability of Env-specific total IgG binding antibody responses to HIV-1 Env proteins assessed by binding antibody multiplex assay (BAMA)
    5. Response rate and magnitude of Env-specific CD4+ and CD8+ T-cell responses measured by intracellular cytokine staining (ICS)
    6. Durability of Env-specific CD4+ and CD8+ T-cell responses measured by intracellular cytokine staining

    Measured: 1, 2 (At week 6); 3,5 (At week 26) and 4,6 (At week 36)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Apr 2021
  2. Study start5 Aug 2022
  3. Primary completion9 Sep 2024
  4. Study completion9 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04844775
Sponsor's protocol ID
EHVA P01/ANRS VRI08
Other IDs
2020-005888-31
Acronym
EHVA P01
Status last verified
Jun 2026
First submitted
24 Mar 2021
Last updated
8 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above) and DNA-HIV-PT123 4mg and CN54gp140/MPLA-L in people with Healthy Adults, run by ANRS, Emerging Infectious Diseases at 4 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in France, Switzerland, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1- Dose Escalation- Any adverse reaction that results in a clinical decision to stop immunisations (time frame: From week 0 up to Week 4). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04844775.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in